2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Tumor-Agnostic
1
Conditions
Leukemia, Myeloid, Acute
25
Myelodysplastic Syndromes
6
Myeloproliferative Disorders
5
Glioma
5
Cholangiocarcinoma
5
Leukemia
3
Wilms Tumor
2
Sarcoma, Ewing
2
Sarcoma
2
Rhabdomyosarcoma
2
Rhabdoid Tumor
2
Recurrence
2
Osteosarcoma
2
Neuroectodermal Tumors, Primitive, Peripheral
2
Neuroblastoma
2
Neoplasm Metastasis
2
Medulloblastoma
2
Lymphoma, Non-Hodgkin
2
Histiocytosis, Langerhans-Cell
2
Hepatoblastoma
2
Hematologic Neoplasms
2
Ependymoma
2
Chondrosarcoma
2
Biliary Tract Neoplasms
2
Xanthogranuloma, Juvenile
1
Pancreatic Ductal Adenocarcinoma
1
Neoplasms, Unknown Primary
1
Neoplasm, Residual
1
Lymphoma, Follicular
1
IDH1-Mutated Malignancies
1
Interventions
Carboplatin
12
Paclitaxel
11
Gemcitabine
11
Capecitabine
7
Irinotecan
6
Fluorouracil
5
Cisplatin
5
Radiotherapy
4
Oxaliplatin
4
Leucovorin
4
Bevacizumab
4
pembrolizumab
3
Filgrastim
3
Etoposide
3
Erlotinib Hydrochloride
3
Cyclophosphamide
3
etoposide phosphate
2
atezolizumab
2
Trastuzumab
2
Topotecan
2
Taxes
2
Surveys and Questionnaires
2
Peripheral Blood Stem Cell Transplantation
2
Magnetic Resonance Spectroscopy
2
Genetic Testing
2
FAPI-46
2
Docetaxel
2
CP protocol
2
Amifostine
2
Albumin-Bound Paclitaxel
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms, Unknown Primary
×
ivosidenib
×
Clear all
NCT03498521
2025-11-19
CUPISCO
Hoffmann-La Roche
Phase 2
Completed
529 enrolled
16 charts